Clinical trials
Osteosarcoma clinical trials
Below are recruiting osteosarcoma clinical trials, each written for real people, not researchers. We’re tracking 77 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Boston, MassachusettsAges 12 years+ - NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT07227571RecruitingPhase 1
CAR T cells for advanced osteosarcoma
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
Seattle, WashingtonAges 1–75 - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT05235165RecruitingPhase 3
Surgery choice for lung spread of osteosarcoma
This Phase 3 trial compares two ways to remove lung metastases (open surgery vs keyhole surgery) in people with osteosarcoma. It aims to see which approach works better and is safer for patients with a limited number of lung spots that can be removed.
Birmingham, AlabamaAges Up to 50 years - NCT07774533RecruitingEarly Phase 1
Imaging osteosarcoma with a new PET tracer
This trial tests a new PET imaging tracer that may help see osteosarcoma tumors more clearly. It is for people whose osteosarcoma has not improved or has returned after standard treatment.
Beijing, Beijing MunicipalityAges 10–80 - NCT07211737RecruitingPhase 1
C7R-GD2 CAR-T cells for osteosarcoma or neuroblastoma
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
Houston, TexasAges 1–24 - NCT04890067Recruiting
Study of localized high-grade bone cancer in younger patients
This is an observational study (it mainly watches and records care) for people with high-grade osteosarcoma in an arm or leg. It may help doctors learn which care approaches work best for younger patients with localized disease.
Aviano, PordenoneAges Up to 40 years - NCT05400603RecruitingPhase 1
Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Atlanta, GeorgiaAges 1 year+ - NCT06492954RecruitingPhase 1
Testing atezolizumab with radiation and surgery for lung-only osteosarcoma
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
Atlanta, GeorgiaAges Up to 50 years - NCT06650514RecruitingPhase 2
OMO-103 for advanced osteosarcoma
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
BarcelonaAges 12 years+ - NCT07479732RecruitingPhase 1/Phase 2
Apatinib with chemo for advanced osteosarcoma
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
BeijingAges 12–65 - NCT07787429RecruitingPhase 2
Comparing two treatments for high-risk bone cancer
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
Warsaw, MazovianAges 5 months–30 years - NCT06892678RecruitingPhase 1/Phase 2
DFMO maintenance for relapsed Ewing sarcoma or osteosarcoma
This trial tests a drug called DFMO given as maintenance therapy to keep cancer from coming back. It is for people under 40 who have finished treatment for relapsed Ewing sarcoma or osteosarcoma and currently show no signs of cancer.
The Bronx, New YorkAges Up to 39 years - NCT07725380RecruitingPhase 1/Phase 2
Two drugs for relapsed sarcoma or osteosarcoma
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Tampa, FloridaAges 12–40 - NCT03721068RecruitingPhase 1
CAR T-cell treatment for hard-to-treat childhood tumors
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
Atlanta, GeorgiaAges 1.5 years+ - NCT03900793RecruitingPhase 1
Losartan plus sunitinib for osteosarcoma after prior treatment
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
Los Angeles, CaliforniaAges 10 years+ - NCT04132895Recruiting
Study to improve outcomes in osteosarcoma care through collaboration
This trial focuses on improving how osteosarcoma care is coordinated and delivered, using collaboration between clinicians. It may help by helping teams make more consistent treatment decisions for people newly diagnosed.
London, Greater LondonAges Any age - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT05588648RecruitingPhase 1/Phase 2
Testing vactosertib for osteosarcoma that keeps coming back
This Phase 1/2 study tests how safe and how well vactosertib works for adolescents and adults with osteosarcoma that has returned, stopped responding, or is getting worse despite prior treatment. You may be able to join if you meet age, cancer, recovery-from-prior-therapy, and health-test requirements.
Cleveland, OhioAges 12 years+ - NCT05830123RecruitingPhase 2
Test drug HS-20093 for osteosarcoma after earlier treatment
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
BeijingAges 18 years+ - NCT05926492RecruitingPhase 2
Surufatinib plus chemotherapy before surgery for osteosarcoma
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
Hangzhou, ZhejiangAges 2–70 - NCT06017518Recruiting
Watching local relapse after high-grade osteosarcoma treatment
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
Bologna, BOAges Any age
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Osteosarcoma trials by city
Studies with a site in or near these metro areas.
Osteosarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for osteosarcoma?
- Yes. Clin2 currently lists 77 recruiting osteosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a osteosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a osteosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.